Defendant Name: GlaxoSmithKline plc 

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 37733W10

Initial Case Details

Legal Case Name In the Matter of GlaxoSmithKline plc
First Document Date 30-Sep-2016
Initial Filing Format Administrative Action
File Number 3-17606
Allegation Type Foreign Corrupt Practices Act
AAER 3810

Violations Alleged

Exchange Act
• Sec 13(b)(2)(A)
• Sec 13(b)(2)(B)

Resolutions

First Resolution Date 30-Sep-2016
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

34-79005 30-Sep-2016 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings, Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order
On September 30, 2016, the SEC issued a settled administrative proceedings against GlaxoSmithKline plc for the violations of the internal controls and recordkeeping provisions of the FCPA.
34-79005-s 30-Sep-2016 Administrative Summary
GlaxoSmithKline Pays $20 Million Penalty to Settle FCPA Violations
On September 30, 2016, the SEC announced that: "GlaxoSmithKline plc (“GSK”) has agreed to pay $20 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales."